"We're seeing this new patient population enter aesthetics with different concerns, different goals, and a strong desire for individualized, long-term treatment and care, particularly when it comes to restoring facial balance and volume." Data Highlights: How GLP-1Associated Weight Loss Is Changing Aesthetic Care The data underscores a broader evolution in the aesthetics landscape
Other GLP-1 receptor agonists that are FDA-approved to treat type 2 diabetes and may lead to weight loss include: Dulaglutide (Trulicity) Exenatide (Bydureon) Lixisenatide (Adlyxin) Other forms of semaglutide (Ozempic and Rybelsus) Many diabetes medications and insulin reduce blood sugars but also contribute to weight gain
Bone health in the elderly with type 2 diabetes mellitusa systematic review
it inhibits angiogenesis and induces copper deficiency through chelation (397)
In December 2024, the FDA abruptly determined that the tirzepatide shortage had resolved and removed these products from its shortage list, effectively terminating compounders' legal authority to produce these drugs
While they arent specifically focused on menopause or women 35+, theyve recently lowered their BMI requirements and offer fast access to both compounded and brand-name GLP-1 medications